Clinical trial
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in…
NCT00479232 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00479232 |
|---|---|
| Title | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) |
| Official title | A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute Myelodysplastic Syndromes, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | vorinostat, decitabine |
| Enrollment | 71 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | May 28, 2007 |
| Last update posted | Sep 21, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: